This report analyzes the merger and acquisition (M&A) activity in Q3 2025 in the Pharma sector.
The global pharma sector in Q3 2025 saw a surge in deal value, with $43.2 billion worth of deals, representing an increase of 36.7% compared to Q2 2025.However, deal volume, declined by 21.9% to 107 M&A deals in Q3 2025. Oncology emerged as the leading therapeutic area recording 32 deals.
The global pharma sector in Q3 2025 saw a surge in deal value, with $43.2 billion worth of deals, representing an increase of 36.7% compared to Q2 2025.However, deal volume, declined by 21.9% to 107 M&A deals in Q3 2025. Oncology emerged as the leading therapeutic area recording 32 deals.
Scope
- This report provides an overview of M&A activity globally in Q3 2025 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q3 2025 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Activity in Q3 2025
2.1 Pharma Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Activity in Pharma
5 Ownership Type: Private Vs Public (Count)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A Activity in Pharma by Deal Size
8 Notable Pharma Deals in Q3 2025
9 Pharma Regional Comparison - Q3 2025
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound Deals in Pharma in Q3 2025
12 Regional M&A Activity in Pharma by Value and Volume
13 Pharma M&A Review by Top 10 Countries
14 Top 10 Therapy Area M&A Review
15 Further Information
15.1 Methodology
16 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co
- Verona Pharma
- Genmab
- Merus
- Pfizer
- Metsera
- F. Hoffmann-La Roche
- 89bio
- Innosera
- Bavarian Nordic
- Sanofi
- Vicebio
- Novartis
- Tourmaline Bio
- Sino Biopharmaceutical
- LaNova Medicines
- Bausch Health Companies
- DURECT
- Serb SAS
- Y-mAbs Therapeutics
